The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Sorafenib vs placebo in treatment-naïve FLT3-ITD AML
Andrew Wei
• 3 Dec 2020
Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, discusses the results of a Phase II study (ALLG AML M16) aiming to evaluate the efficacy a combined sorafenib and chemotherapy treatment in previously untreated FLT3-ITD acute myeloid leukemia (AML) patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
